CN102908347A - 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 - Google Patents

取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 Download PDF

Info

Publication number
CN102908347A
CN102908347A CN2012103943126A CN201210394312A CN102908347A CN 102908347 A CN102908347 A CN 102908347A CN 2012103943126 A CN2012103943126 A CN 2012103943126A CN 201210394312 A CN201210394312 A CN 201210394312A CN 102908347 A CN102908347 A CN 102908347A
Authority
CN
China
Prior art keywords
phenyl
alkyl
formula
bromo
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012103943126A
Other languages
English (en)
Chinese (zh)
Inventor
K.J.L.M.安德里斯
J.F.E.范格斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102908347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN102908347A publication Critical patent/CN102908347A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2012103943126A 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 Pending CN102908347A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102402.7 2004-05-28
EP04102402 2004-05-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800170162A Division CN1976704B (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Publications (1)

Publication Number Publication Date
CN102908347A true CN102908347A (zh) 2013-02-06

Family

ID=34929150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800170162A Expired - Fee Related CN1976704B (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN2012103943126A Pending CN102908347A (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2005800170162A Expired - Fee Related CN1976704B (zh) 2004-05-28 2005-05-24 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR101371653B1 (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107243008A (zh) * 2017-04-13 2017-10-13 中国科学院广州生物医药与健康研究院 吡唑并[1,5‑a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN108349898A (zh) * 2015-10-20 2018-07-31 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
CN110804016A (zh) * 2019-12-05 2020-02-18 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
CN111278985A (zh) * 2017-09-01 2020-06-12 学校法人北里研究所 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
CN114129526A (zh) * 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005005810T2 (de) * 2004-05-28 2009-04-09 Janssen Pharmaceutica N.V. Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
LT1898909T (lt) * 2005-06-28 2017-02-10 Janssen Pharmaceutica Nv Chinolino dariniai kaip antibakteriniai agentai
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CA2772786A1 (en) * 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof
CN102249935B (zh) 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
RU2664587C1 (ru) * 2014-07-14 2018-08-21 Шанхай Цзя Тань Фарматек Ко. Лтд. Производные пиридина и их применение против микобактерий
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
US10508097B2 (en) * 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
CA3163103A1 (en) 2019-11-26 2021-06-03 Nanyang Technological University Compounds for treating tuberculosis
CN116406270A (zh) 2020-11-12 2023-07-07 詹森药业有限公司 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
IL320832A (en) * 2022-11-15 2025-07-01 Lilly Co Eli AHR agonists
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
CA2493225A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李端: "《药理学》", 31 December 1987, 人民卫生出版社 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114129526A (zh) * 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN108349898A (zh) * 2015-10-20 2018-07-31 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
CN107243008A (zh) * 2017-04-13 2017-10-13 中国科学院广州生物医药与健康研究院 吡唑并[1,5‑a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN111278985A (zh) * 2017-09-01 2020-06-12 学校法人北里研究所 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
CN111278985B (zh) * 2017-09-01 2023-09-08 学校法人北里研究所 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
CN110804016A (zh) * 2019-12-05 2020-02-18 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用

Also Published As

Publication number Publication date
HK1106136A1 (en) 2008-03-07
JP5081617B2 (ja) 2012-11-28
AP2006003828A0 (en) 2006-12-31
NO20066041L (no) 2007-02-27
AU2005249231B2 (en) 2010-11-11
EP1753427B1 (en) 2008-04-02
EP1753427A1 (en) 2007-02-21
KR20130024969A (ko) 2013-03-08
US20070249667A1 (en) 2007-10-25
TWI363625B (en) 2012-05-11
JO2524B1 (en) 2010-03-17
WO2005117875A1 (en) 2005-12-15
CY1110388T1 (el) 2015-04-29
UA90267C2 (ru) 2010-04-26
EA200602260A1 (ru) 2007-04-27
NZ550840A (en) 2010-01-29
CA2566544A1 (en) 2005-12-15
US20100168133A1 (en) 2010-07-01
ME01105B (me) 2013-03-20
EA010651B1 (ru) 2008-10-30
CN1976704A (zh) 2007-06-06
ZA200609899B (en) 2009-01-28
CA2566544C (en) 2012-04-17
RS50585B (sr) 2010-05-07
AR049127A1 (es) 2006-06-28
IL179630A (en) 2011-05-31
BRPI0510414A (pt) 2007-10-23
JP2008500992A (ja) 2008-01-17
CN1976704B (zh) 2012-12-05
KR20070017393A (ko) 2007-02-09
AU2005249231A1 (en) 2005-12-15
AP2037A (en) 2009-10-09
TW200608974A (en) 2006-03-16
ES2306146T3 (es) 2008-11-01
SI1753427T1 (sl) 2008-10-31
PA8635201A1 (es) 2006-05-16
NO338624B1 (no) 2016-09-19
PL1753427T3 (pl) 2008-09-30
DE602005005810T2 (de) 2009-04-09
JP2012229239A (ja) 2012-11-22
IL179630A0 (en) 2007-07-04
ATE390925T1 (de) 2008-04-15
DE602005005810D1 (de) 2008-05-15
MY140611A (en) 2009-12-31
MXPA06013888A (es) 2007-01-26
BRPI0510414B1 (pt) 2022-04-05
KR101371653B1 (ko) 2014-03-07
PT1753427E (pt) 2008-07-04
CL2009001980A1 (es) 2010-04-16
JP5675718B2 (ja) 2015-02-25
HRP20080307T3 (hr) 2008-07-31
DK1753427T3 (da) 2008-07-21

Similar Documents

Publication Publication Date Title
CN102908347A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN103142595A (zh) 用于治疗潜伏性结核的喹啉衍生物
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
CN101277740B (zh) 包含*唑化合物的抗结核组合物
US7491721B2 (en) Antimycobacterial pharmaceutical composition
HK1177427A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1106136B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CN101087608A (zh) 用于治疗潜伏性结核的喹啉衍生物
US20110065723A1 (en) Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof
CN108472292A (zh) 药物组合物、固定剂量的甲氟喹的用途和用于治疗结核病的方法
TW202146024A (zh) 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合
HK1098962B (en) Antimycobacterial pharmaceutical composition comprising an antitubercular drug
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177427

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130206

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1177427

Country of ref document: HK